News
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...
Alongside her husband, Bob Duggan, Maky Zanganeh has guided cancer drug developer Summit Therapeutics to reach staggering new ...
Shares of Summit Therapeutics surged 9.7% to $25.81 in morning trade. The Menlo Park, California-based drug developer did not immediately respond to Reuters' request seeking comment, ...
Second, SoFi could grow its revenue even without expanding its membership base, by cross-selling additional products to its ...
Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a note issued ...
Zacks Investment Research on MSN3d
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to TradeShares of Summit Therapeutics PLC (SMMT) have gained 2.8% over the past four weeks to close the last trading session at $21.2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback